Tvardi Therapeutics, Inc.(TVRD US)
$1.37-0.042.84%
- Pricing and plans
Get the full experience
We save the real magic for signed-in users.
Get the full experience
We save the real magic for signed-in users.
Get the full experience
We save the real magic for signed-in users.
| Millions USD (ex. Per Share) | FY202012/31/2020 | FY202112/31/2021 | FY202212/31/2022 | FY202312/31/2023 | FY202412/31/2024 | FY202512/31/2025 | Last 12M03/31/2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.0 | 7.1 | - | - | |||||
| -Cost of Revenue | 6.4 | 0.8 | 0.1 | 0.0 | |||||
| Gross Profit | 14.5 | 6.3 | -0.1 | -0.0 | |||||
| -Operating Expenses | 136.0 | 62.1 | 26.7 | 29.4 | |||||
| +Selling, General & Admin | 27.6 | 26.4 | 8.7 | 9.6 | |||||
| +General And Administrative Expenses | - | - | 8.7 | 9.6 | |||||
| +Research and Development | 108.4 | 32.8 | 18.0 | 19.8 | |||||
| +Other Operating Expenses | - | 3.0 | - | -0.0 | |||||
| Operating Income | -121.5 | -55.8 | -26.7 | -29.4 | |||||
| +Non Operating Income | 4.3 | -21.1 | 9.9 | 15.4 | |||||
| +Interest Income, Net | 1.3 | -5.6 | 1.4 | 1.3 | |||||
| +Interest Income | 1.3 | 2.8 | 1.4 | 1.3 | |||||
| -Interest Expense | - | 8.5 | - | - | |||||
| +Other Non-Op Income | 3.0 | -15.5 | 8.5 | 14.0 | |||||
| Pretax Income | -118.5 | -71.3 | -18.2 | -15.4 | |||||
| -Income Tax Expense | - | -0.4 | - | - | |||||
| Income from Cont Ops | -118.5 | -70.9 | -18.2 | -15.4 | |||||
| -Net Extraordinary Losses | - | - | - | - | |||||
| +Discounted operations | - | - | - | - | |||||
| +XO & Accounting Changes | - | - | - | - | |||||
| Income Incl. MI | -118.5 | -70.9 | -18.2 | -15.4 | |||||
| -Minority Interests | - | - | - | - | |||||
| Net Income, GAAP | -118.5 | -70.9 | -18.2 | -15.4 | |||||
| -Prfrrd Div & Other | - | - | 7.2 | 12.7 | |||||
| Net Income Avail To Common | -118.5 | -70.9 | -25.4 | -28.1 | |||||
| Weighted Average Shs Out | 9,355,542 | 1,520,912 | 7,419,060 | 36,331,928 | |||||
| EPS | -1.9 | -46.6 | -2.5 | -1.6 | |||||
| Weighted Average Shs Out Dil | 9,355,542 | 1,520,912 | 7,783,182 | 36,594,465 | |||||
| EPS Diluted | -1.9 | -46.6 | -3.3 | -3.1 | |||||
| Millions USD (ex. Per Share) | FY202012/31/2020 | FY202112/31/2021 | FY202212/31/2022 | FY202312/31/2023 | FY202412/31/2024 | FY202512/31/2025 | Last 12M03/31/2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.0 | 7.1 | - | - | |||||
| -Cost of Revenue | 6.4 | 0.8 | 0.1 | 0.0 | |||||
| Gross Profit | 14.5 | 6.3 | -0.1 | -0.0 | |||||
| -Operating Expenses | 136.0 | 62.1 | 26.7 | 29.4 | |||||
| +Selling, General & Admin | 27.6 | 26.4 | 8.7 | 9.6 | |||||
| +General And Administrative Expenses | - | - | 8.7 | 9.6 | |||||
| +Research and Development | 108.4 | 32.8 | 18.0 | 19.8 | |||||
| +Other Operating Expenses | - | 3.0 | - | -0.0 | |||||
| Operating Income | -121.5 | -55.8 | -26.7 | -29.4 | |||||
| +Non Operating Income | 4.3 | -21.1 | 9.9 | 15.4 | |||||
| +Interest Income, Net | 1.3 | -5.6 | 1.4 | 1.3 | |||||
| +Interest Income | 1.3 | 2.8 | 1.4 | 1.3 | |||||
| -Interest Expense | - | 8.5 | - | - | |||||
| +Other Non-Op Income | 3.0 | -15.5 | 8.5 | 14.0 | |||||
| Pretax Income | -118.5 | -71.3 | -18.2 | -15.4 | |||||
| -Income Tax Expense | - | -0.4 | - | - | |||||
| Income from Cont Ops | -118.5 | -70.9 | -18.2 | -15.4 | |||||
| -Net Extraordinary Losses | - | - | - | - | |||||
| +Discounted operations | - | - | - | - | |||||
| +XO & Accounting Changes | - | - | - | - | |||||
| Income Incl. MI | -118.5 | -70.9 | -18.2 | -15.4 | |||||
| -Minority Interests | - | - | - | - | |||||
| Net Income, GAAP | -118.5 | -70.9 | -18.2 | -15.4 | |||||
| -Prfrrd Div & Other | - | - | 7.2 | 12.7 | |||||
| Net Income Avail To Common | -118.5 | -70.9 | -25.4 | -28.1 | |||||
| Weighted Average Shs Out | 9,355,542 | 1,520,912 | 7,419,060 | 36,331,928 | |||||
| EPS | -1.9 | -46.6 | -2.5 | -1.6 | |||||
| Weighted Average Shs Out Dil | 9,355,542 | 1,520,912 | 7,783,182 | 36,594,465 | |||||
| EPS Diluted | -1.9 | -46.6 | -3.3 | -3.1 | |||||